<DOC>
	<DOCNO>NCT01143805</DOCNO>
	<brief_summary>In study , 10 mg dose CP-690,550 give study subject two separate occasion two different route administration : One time mouth tablet form one time vein ( intravenous form ) . The amount CP-690,550 available blood follow administration vein measure expected reflect maximum amount possible 10 mg CP-690,550 dose . The amount CP-690,550 achieve blood follow oral tablet administration also measure compare achieved follow administration vein order estimate much maximum amount possible actually absorb blood follow administration mouth tablet .</brief_summary>
	<brief_title>A Study To Estimate The Amount Of CP-690,550 ( Study Drug ) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form</brief_title>
	<detailed_description>To estimate absolute bioavailability 10 mg oral dose tasocitinib ( CP-690,550 ) compare 10 mg intravenous dose tasocitinib ( CP-690,550 ) healthy subject .</detailed_description>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female ( non childbearing potential ) Subjects age 21 55 year , inclusive Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) No evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) Evidence history clinically significant illness , medical condition , disease . 2 . Evidence history clinically significant infection within past 3 month . 3 . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Absolute Bioavailability</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>